পদ্ধতির তুলনা করুন

	ডিসএবিলিটি-অ্যাডজাস্টেড লাইফ ইয়ার (DALY)	ব্যয়-কার্যকারিতা বিশ্লেষণ (CEA)
ক্ষেত্র	স্বাস্থ্য অর্থনীতি	স্বাস্থ্য অর্থনীতি
পরিবার	Process / pipeline	Process / pipeline
উদ্ভবের বছর	1990	1984
প্রবর্তক	Christopher J. L. Murray and Alan D. Lopez (World Health Organization / World Bank)	Drummond & Stoddart (Health Economics Research Group, McMaster University)
ধরন	Method	Method
মৌলিক উৎস	Murray, C. J., Lopez, A. D., & Jamison, D. T. (1994). The Global Burden of Disease in 1990: Summary Results, Sensitivity Analysis, and Future Directions. In C. J. Murray & A. D. Lopez (Eds.), Global Burden of Disease and Injury. Cambridge: Harvard University Press.	Gold, M. R., Siegel, J. E., Russell, L. B., & Weinstein, M. C. (Eds.). (1996). Cost-Effectiveness in Health and Medicine. New York: Oxford University Press.
অপর নাম	DALY, global disease burden metric, burden of disease	CEA, ICER, Incremental Cost-Effectiveness Ratio
সম্পর্কিত	5	5
সারসংক্ষেপ	A DALY quantifies disease burden as the sum of years of life lost to premature death and years lived with disability. Developed by the World Health Organization and World Bank in 1990 as part of the Global Burden of Disease (GBD) study, DALYs enable epidemiologists and public health planners to compare disease burden across populations, identify health priorities, and evaluate intervention impact. One DALY = one lost year of 'healthy' life; DALYs averted measure progress toward health goals.	Cost-effectiveness analysis compares the incremental cost per unit of health benefit gained by one intervention relative to a comparator (standard care or best alternative). Developed rigorously in the 1980s by Drummond, Stoddart, and colleagues, CEA is now the standard framework for technology appraisal globally. NICE, HAS, CADTH, and other health technology assessment bodies use CEA to decide which treatments warrant public funding and at what price.